Effectiveness of Allergy Shots: The Evidence Pyramid
The effectiveness of allergy shots is best evaluated through an evidence pyramid. At the apex: three Cochrane meta-analyses — Calderón 2007 (51 RCTs, symptom SMD −0.73), Abramson 2010 (88 asthma trials, NNT=3), Boyle 2012 (venom, 2.7% vs 39.8%). Middle: landmark RCTs including Durham 1999 (durable remission) and Jacobsen 2007 (asthma prevention OR 4.6). Base: real-world Tkacz 2021 — only 43.9% of US starters reach maintenance.
8 peer-reviewed sources
The evidence pyramid for allergy shots places Cochrane meta-analyses (symptom SMD −0.73) at the apex, landmark RCTs in the middle, and real-world US adherence data (43.9% reach maintenance) at the base. The apex is excellent; the base constrains real-world access to it.
The essentials
The Cochrane and RCT effect sizes documented in the evidence pyramid assume the extract matches the dominant sensitization — Curex at-home IgE testing with board-certified allergist review identifies that dominant allergen, so SCIT effectiveness reproduces the trial-level numerical effects rather than a diluted multi-allergen-vial average. For eligible maintenance patients, Curex then delivers that SCIT as one weekly self-administered shot at home for $129/month — a serum sterile-compounded to USP <797> standards, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand, so the trial-level effect sizes are pursued without the weekly-clinic burden.
Evaluating the effectiveness of allergy shots requires climbing the evidence pyramid rather than relying on any single study or anecdote. Here is what each level shows.
Level 1 — Cochrane systematic reviews (apex). Calderón MA et al. (Cochrane 2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) synthesized 51 double-blind, placebo-controlled RCTs involving 2,871 patients in seasonal allergic rhinitis: symptom SMD −0.73 (95% CI −0.97 to −0.50); medication SMD −0.57 (95% CI −0.82 to −0.33). Both are statistically significant at P<0.00001. For asthma, Abramson MJ et al. (Cochrane 2010, CD001186, DOI 10.1002/14651858.CD001186.pub2) synthesized 88 SCIT trials: symptom SMD −0.59; NNT = 3 to prevent one patient's asthma deterioration. For Hymenoptera venom, Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of treated versus 39.8% untreated (RR 0.10, 95% CI 0.03–0.28).
Level 2 — Landmark RCTs. Durham SR et al. (NEJM 1999;341:468–475, DOI 10.1056/NEJM199908123410702): clinical remission sustained at least 3 years after stopping a 3–4 year grass course — the definitive disease-modification evidence. Walker SM et al. (JACI 2001;107:87–93, DOI 10.1067/mai.2001.112027): approximately 49% symptom reduction and approximately 80% medication-score reduction for grass SCIT. Creticos PS et al. (NEJM 1996;334:501–506, DOI 10.1056/NEJM199602223340804): ragweed SCIT significant in-season symptom reduction. Alvarez-Cuesta E et al. (JACI 1994;93:556–566) and Varney VA et al. (Clin Exp Allergy 1997;27:860–867): cat SCIT ~62% symptom reduction. Kuna P et al. (JACI 2011;127:502–508, DOI 10.1016/j.jaci.2010.11.036): Alternaria pediatric 63.5% combined symptom-score reduction year 3.
Level 3 — Pediatric asthma prevention. Jacobsen L et al. (Allergy 2007;62:943–948, DOI 10.1111/j.1398-9995.2007.01451.x): OR 4.6 (95% CI 1.5–13.7) for remaining asthma-free at 10-year follow-up after 3 years of pediatric SCIT. Niggemann B et al. (Allergy 2006;61:855–859) confirmed the 5-year intermediate data. This is a level of evidence — prospective longitudinal prevention outcome — unavailable for any pharmacotherapy.
Level 4 — Real-world cohorts (base). Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, DOI 10.1080/03007995.2021.1903848, MarketScan n=103,207): only 43.9% of US AIT starters reached maintenance; 23.9% never returned after their first injection. Hankin CS et al. (JACI 2013;131:1084–1091, DOI 10.1016/j.jaci.2012.12.662) Florida Medicaid 1997–2009: SCIT associated with significantly reduced total healthcare costs versus matched controls. AAAAI/ACAAI surveillance (Epstein TG et al., JACIP 2014;2:161–167): 0.1% systemic-reaction rate stable across 23.3 million injection visits.
The honest synthesis: the apex of the pyramid supports moderate, durable, disease-modifying effectiveness when SCIT is correctly targeted and patients sustain the 3–5 year course (Cox L et al., JACI 2011;127[1 Suppl]:S1–S55, DOI 10.1016/j.jaci.2010.09.034). The base tells us that fewer than half of US patients access the apex.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
The evidence pyramid organizes SCIT effectiveness by study design quality. Per-allergen RCT data falls at Level 2; the Cochrane aggregate is Level 1; real-world adherence data is Level 4.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The evidence pyramid comparison shows SCIT has the most robust apex of all allergy treatments — but the base (adherence) is where the real-world gap exists. The fix is the delivery setting: the allergy shot can now be self-administered at home, so eligible maintenance patients keep SCIT's apex-level evidence while shedding the weekly-clinic visits that drive the adherence gap. SLIT's daily at-home dosing is a parallel needle-free route to the same goal.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
Pharmacotherapy |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients where the evidence-pyramid base (Tkacz 2021 adherence) is the binding constraint, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed by a board-certified allergist and self-administered as one weekly shot at home for $129/month. Your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand — closing the gap between RCT-grade effectiveness and real-world adherence.
See if at-home shots are right for youFrequently asked questions
What is the highest-quality evidence for allergy shot effectiveness?
The highest-quality evidence comes from Cochrane systematic reviews, which sit at the apex of the evidence pyramid. Calderón MA et al. (Cochrane 2007, CD001936) synthesized 51 double-blind, placebo-controlled RCTs involving 2,871 patients in seasonal allergic rhinitis and found symptom SMD −0.73 (P<0.00001) and medication SMD −0.57 (P<0.00001). Abramson MJ et al. (Cochrane 2010, CD001186) synthesized 88 SCIT trials for asthma and found NNT = 3. Boyle RJ et al. (Cochrane 2012, PMID 23076950) synthesized venom immunotherapy evidence and found 2.7% versus 39.8% subsequent systemic sting reactions. These three Cochrane reviews collectively represent the best evidence available for any allergy treatment — higher in the evidence hierarchy than any single RCT or observational study.
How does real-world effectiveness compare to Cochrane evidence?
Real-world US effectiveness falls substantially below the Cochrane apex, primarily because of adherence failure. Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, MarketScan n=103,207) found that only 43.9% of US immunotherapy starters reached maintenance and 23.9% never returned after their first injection. The Cochrane effect sizes were derived from clinical trial populations that completed the protocol — meaning they represent the effectiveness achievable by patients who sustain treatment, not the population-level effectiveness accounting for dropout. Hankin CS et al. (JACI 2013;131:1084–1091) found favorable healthcare cost data in Florida Medicaid starters, but again only among patients who continued treatment.
Is there evidence that allergy shots have durable benefits after stopping?
Yes — the durability evidence is particularly strong. Durham SR et al. (NEJM 1999;341:468–475) randomized patients who had completed 3–4 years of grass SCIT to continue or discontinue; the discontinuation group maintained clinical remission comparable to the continuation group for at least 3 further years, with persistent immunologic changes (elevated IgG4, inverted IgE/IgG4 ratio, reduced skin-test reactivity). Cox and Cohn (Ann Allergy Asthma Immunol 2007, PMID 17521025) reviewed post-treatment relapse data and found relapse rates of 0%–55% across studies — 0% at the low end for grass pollen, up to 55% for dust mite — which is why the decision to stop is individualized by allergen. No pharmacotherapy produces post-treatment benefit.
How does the PAT study evidence fit into the evidence pyramid?
The PAT (Preventive Allergy Treatment) study sits at Level 2–3 of the evidence pyramid as a prospective longitudinal RCT with 10-year follow-up. Möller C et al. (JACI 2002) provided 3-year data; Niggemann B et al. (Allergy 2006;61:855–859) provided 5-year data; Jacobsen L et al. (Allergy 2007;62:943–948) provided 10-year data showing OR 4.6 (95% CI 1.5–13.7) for remaining asthma-free. This is unusually robust longitudinal evidence for a preventive outcome in a disease that develops over years. The PAT study is European (grass and birch allergens) and had an unblinded control arm for the follow-up phase, which limits the evidence grade — but no other prospective pediatric SCIT data matches its follow-up duration.
What real-world data exists on allergy shot effectiveness?
The most important US real-world dataset is Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, MarketScan commercial-claims database, n=103,207 immunotherapy patients, DOI 10.1080/03007995.2021.1903848). Key findings: only 43.9% reached maintenance; 23.9% never returned after their first injection; mean total annual healthcare cost $10,431 ± $16,606. Stone B et al. (Allergy Asthma Proc 2021;42:55–64) characterized this dropout as the primary barrier to real-world effectiveness. Hankin CS et al. (JACI 2013;131:1084–1091, Florida Medicaid 1997–2009) found SCIT associated with significantly reduced total healthcare costs versus matched controls — supporting favorable cost-effectiveness for patients who sustain treatment. AAAAI/ACAAI surveillance (Epstein 2014) provides the safety denominator of 23.3 million injection visits.
For which allergens does the evidence pyramid have the most evidence?
The evidence pyramid is most robust for grass pollen, Hymenoptera venom, cat dander, ragweed, and Alternaria mold. Grass pollen has multiple high-quality RCTs (Durham 1999, Walker 2001) plus representation in the Cochrane seasonal-AR meta-analysis. Hymenoptera venom has its own Cochrane review (Boyle 2012) and the landmark Hunt 1978 NEJM trial. Cat has two European RCTs (Alvarez-Cuesta 1994, Varney 1997) plus FDA-standardized extract. Ragweed has Creticos 1996 NEJM. Alternaria has two well-controlled pediatric RCTs (Kuna 2011; Tabar 2019). Dust mite SCIT evidence is less robust than SLIT-tablet evidence — the strongest modern HDM data is SLIT-tablet (Mosbech 2014). Mountain cedar, non-Alternaria molds, and most insect-pollinated trees sit near the pyramid base with limited or no controlled SCIT trial evidence.
Related Articles
Purpose of Allergy Shots: Mechanism & Clinical Intent
Allergy shots induce immune tolerance — IgE to IgG4. Three intents: symptom relief (Cochrane SMD −0.73), less medication, and durable disease modification.
Read moreAllergy Shots Effectiveness – RCT Evidence | Curex
Allergy shots effectiveness: Cochrane SMD −0.73 (51 RCTs, 2,871 patients). Per allergen: venom 95%+, grass 80%, cat 62%, Alternaria 63.5%. Real-world ceiling: 43.9% reach maintenance.
Read moreCluster Allergy Shots: Schedule & Safety | Curex
Cluster allergy shots reach maintenance in 4–8 weeks vs 6 months. Schedule, the 3× higher per-injection reaction rate, and who qualifies (Tabar 2005).
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreAllergy Shots Benefits – QoL & Outcomes | Curex Guide
Allergy shots benefits: QoL RQLQ 0.8 (Walker 2001), symptom SMD -0.73, medication SMD -0.57, asthma prevention OR 4.6, >=3-yr post-treatment remission.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.